恶性腹腔积液的分子机制及治疗进展  

Molecular mechanism and treatment progress of malignant peritoneal effusion

作　　者：刘会岭 陈兴秀[1] 蔡小萍 毕益明[1] 刘毅 LIU Hui-ling;CHEN Xing-xiu;CAI Xiao-ping;BI Yi-ming;LIU Yi(Binzhou People's Hospital,Binzhou,Shandong Province 256600)

机构地区：[1]滨州市人民医院肿瘤二科,山东滨州256600

出　　处：《消化肿瘤杂志（电子版）》2018年第4期179-182,共4页Journal of Digestive Oncology(Electronic Version)

基　　金：山东省适宜卫生技术疼痛科推广项目(腹腔化疗治疗恶性腹水的推广应用)

摘　　要：恶性腹腔积液(malignant peritoneal ascites,MPE)是由恶性肿瘤局部侵犯腹膜或者转移所引起的液体在腹膜腔内的病理性聚积,常提示恶性肿瘤复发或晚期,预后差。原发肿瘤的位置不同,MPE的形成机制不同。腹膜转移所引起的MPE,其产生机制与腹膜本身结构的特征及多种蛋白酶、黏附分子、细胞因子及血管生成因子等的协同参与有关。目前MPE可采用全身化疗、局部治疗、全身化疗联合局部治疗等多种治疗方式。本文就腹腔积液形成的机制,尤其是腹膜转移机制方面进行综述,同时探讨MPE的治疗进展。Malignant peritoneal ascites(MPE)is the pathological accumulation of malignant peritoneal fluid in the peritoneal cavity caused by local invasion or metastasis of malignant tumors,which often indicates that malignant tumors are recurrent or advanced with poor prognosis.The formation mechanism of MPE varies with the location of primary tumor.The mechanism of MPE induced by peritoneal metastasis is related to the characteristics of peritoneal structure and the synergistic participation of various proteases,adhesion molecules,cytokines and angiogenesis factors.At present,MPE can be treated by systemic chemotherapy,local treatment,systemic chemotherapy combined with local treatment and other treatment methods.This article reviews the mechanism of peritoneal effusion formation,especially peritoneal metastasis,and discusses the progress of MPE therapy.

关 键 词：恶性腹腔积液 腹膜转移 腹腔化疗 

分 类 号：R730.5[医药卫生—肿瘤]